Biologics & Biosimilars · Prescription Drugs
Amgen revenue, results and funding
Amgen filed revenue of $36.8B for 2025.
Data updated Nov 18, 2026 · Back to the company report
$36.8BRevenue, 2025
$7.7BNet income, 2025
Results by year
| Year | Revenue | Net income | Total assets | LANG_CR_S_M_TAX_PAID | LANG_CR_S_M_TAX_EXPENSE | LANG_CR_S_M_DIVIDENDS | LANG_CR_S_M_BUYBACKS | LANG_CR_S_M_CAPEX | LANG_CR_S_M_SBC | LANG_CR_S_M_RND | LANG_CR_S_M_OPERATING_INCOME | LANG_CR_S_M_CASH | LANG_CR_S_M_DEBT | LANG_CR_S_M_ACQUISITIONS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $36.8B | $7.7B | $90.6B | $4.3B | $1.3B | $5.1B | $0 | $1.9B | $494M | $7.3B | $9.1B | $9.1B | $50B | $53M |
| 2024 | $33.4B | $4.1B | $91.8B | $2.9B | $519M | $4.8B | $200M | $1.1B | $530M | $6B | $7.3B | $12B | $56.5B | $0 |
| 2023 | $28.2B | $6.7B | $97.2B | $3.4B | $1.1B | $4.6B | $0 | $1.1B | $431M | $4.8B | $7.9B | $10.9B | $63.2B | $27B |
| 2022 | $26.3B | $6.6B | $65.1B | $2.4B | $794M | $4.2B | $6.4B | $936M | $401M | $4.4B | $9.6B | $7.6B | $37.4B | $3.8B |
| 2021 | $26B | $5.9B | $61.2B | $1.9B | $808M | $4B | $5B | $880M | $341M | $4.8B | $7.6B | $8B | $33.2B | $2.5B |
| 2020 | $25.4B | $7.3B | $62.9B | $1.4B | $869M | $3.8B | $3.5B | $608M | $330M | $4.2B | $9.1B | $6.3B | $32.9B | $0 |
| 2019 | $23.4B | $7.8B | $59.7B | $1.9B | $1.3B | $3.5B | $7.7B | $618M | $308M | $4.1B | $9.7B | $6B | $27B | $13.6B |
| 2018 | $23.7B | $8.4B | $66.4B | $1.9B | $1.2B | $3.5B | $17.8B | $738M | $311M | $3.7B | $10.3B | $6.9B | $29.5B | −$195M |
| 2017 | $22.8B | $2B | $80B | $1.5B | $7.6B | $3.4B | $3.2B | $664M | $329M | $3.6B | $10B | $3.8B | $34.2B | $19M |
| 2016 | $23B | $7.7B | $77.6B | $1.1B | $1.4B | $3B | $3B | $738M | $311M | $3.8B | $9.8B | $3.2B | $30.2B | $0 |
| 2015 | $21.7B | $6.9B | $71.4B | $919M | $1B | $2.4B | $1.9B | $594M | $322M | $4.1B | $8.5B | $4.1B | $29.2B | $359M |
| 2014 | $20.1B | $5.2B | $69B | $269M | $427M | $1.9B | $138M | $718M | $408M | $4.3B | $6.2B | $3.7B | $30.2B | $165M |
| 2013 | $18.7B | $5.1B | $66.1B | $321M | $184M | $1.4B | $832M | $693M | $403M | $4.1B | $5.9B | $3.8B | $29.6B | $9.4B |
| 2012 | $17.3B | $4.3B | $54.3B | $502M | $664M | $1.1B | $4.6B | $689M | $362M | $3.4B | $5.6B | $3.3B | $26.5B | $2.4B |
| 2011 | $15.6B | $3.7B | $48.9B | $595M | $467M | $500M | $8.3B | $567M | $341M | $3.2B | $4.3B | $6.9B | $21.4B | $701M |
Sources: SEC
How to cite
Amgen, Financials. Alion, Nov 18, 2026. https://alion.io/company/amgen/financials
